Annual report
2533.TEDINET S100VG4C
Period2024-01-01 → 2024-12-31
Filed2025-03-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 147
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥84.1bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥84.9bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥81.1bn | 2022-01-01 → 2022-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥78.6bn | 2021-01-01 → 2021-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥77.7bn | 2020-01-01 → 2020-12-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥3.4bn | 2024-01-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | ¥3.6bn | 2023-01-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.6bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.7bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥645m | 2022-01-01 → 2022-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2021-01-01 → 2021-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2020-01-01 → 2020-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.6bn | 2024-01-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2023-01-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.7bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥299m | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.7bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | ¥3.4bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥55.7bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥55.4bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥55.5bn | at 2022-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥52.3bn | at 2021-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥51.7bn | at 2020-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥31.3bn | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥33.2bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥24.5bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥22.2bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥19.6bn | at 2022-12-31d | Cons. | Net assets |
| Net assets / equity | ¥22.0bn | at 2021-12-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥22.1bn | at 2020-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥887m | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥828m | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥882m | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥824m | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥894m | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥986m | at 2021-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥910m | at 2020-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥4.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.6bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥860m | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.8bn | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥11m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.0bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.9bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.5bn | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥2.9bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.7bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥4.8bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.4bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.5bn | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥47.39 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.3 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-21.22 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.03 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.26 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥414.62 | at 2024-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥367.3 | at 2023-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥305.21 | at 2022-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥336.73 | at 2021-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥336.41 | at 2020-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 42.4% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.6% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.0% | at 2022-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.3% | at 2021-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.7% | at 2020-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 12.1% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.8% | 2020-01-01 → 2020-12-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 808 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 787 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 803 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 879 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 908 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥3.0bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥2.7bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥2.3bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.8bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | ¥1.6bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥1.8bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.5bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥956m | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.8bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.7bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | ¥1.5bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥1.4bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥766m | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥839m | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥716m | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥38.0bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥37.9bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥38.5bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥34.8bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥33.4bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥18.8bn | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥19.6bn | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥19.2bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥18.3bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥16.7bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥16.6bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥16.2bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥104m | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥107m | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥26.64 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.53 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥12.95 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.13 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥12.03 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥10 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8 | 2023-01-01 → 2023-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2022-01-01 → 2022-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥7 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥7 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥336.51 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥314.32 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥287.56 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥279.87 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥272.03 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 50.5% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.3% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.5% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.8% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.4% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2023-01-01 → 2023-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 65,586,196 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 65,586,196 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 65,586,196 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 65,586,196 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 65,586,196 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 21 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 24 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 28 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 37 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 44 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 81
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-01-01 → 2024-12-31 | ¥0 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-12-31 | ¥99m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-12-31 | ¥88m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥10m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-12-31 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-12-31 | ¥13m |
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥118m |
| Reconciling Itemsreconciling | depreciation | 2024-01-01 → 2024-12-31 | ¥103m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥25m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥25m |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | ¥5.4bn |
| Enzymatic Medicinereportable segment | capex | 2024-01-01 → 2024-12-31 | ¥282m |
| Enzymatic Medicinereportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥250m |
| Enzymatic Medicinereportable segment | employees | at 2024-12-31 | 117 pure |
| Enzymatic Medicinereportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥4.2bn |
| Enzymatic Medicinereportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥4.2bn |
| Enzymatic Medicinereportable segment | segment assets | at 2024-12-31 | ¥3.8bn |
| Enzymatic Medicinereportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥534m |
| Liquorreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥1.2bn |
| Liquorreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥1.3bn |
| Liquorreportable segment | employees | at 2024-12-31 | 669 pure |
| Liquorreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥78.7bn |
| Liquorreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥78.7bn |
| Liquorreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥15m |
| Liquorreportable segment | segment assets | at 2024-12-31 | ¥40.5bn |
| Liquorreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥2.3bn |
| Real Estatereportable segment | capex | 2024-01-01 → 2024-12-31 | ¥20m |
| Real Estatereportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥281m |
| Real Estatereportable segment | employees | at 2024-12-31 | 1 pure |
| Real Estatereportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥1.1bn |
| Real Estatereportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥1.1bn |
| Real Estatereportable segment | segment assets | at 2024-12-31 | ¥6.0bn |
| Real Estatereportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥604m |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥1.5bn |
| —segment total | depreciation | 2024-01-01 → 2024-12-31 | ¥1.8bn |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥84.0bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥84.0bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥15m |
| —segment total | segment assets | at 2024-12-31 | ¥50.3bn |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥3.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-01-01 → 2023-12-31 | ¥0 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-01-01 → 2023-12-31 | ¥87m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-01-01 → 2023-12-31 | ¥87m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-12-31 | ¥39m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-01-01 → 2023-12-31 | ¥12m |
| Reconciling Itemsreconciling | capex | 2023-01-01 → 2023-12-31 | ¥42m |
| Reconciling Itemsreconciling | depreciation | 2023-01-01 → 2023-12-31 | ¥100m |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥14m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥14m |
| Reconciling Itemsreconciling | segment assets | at 2023-12-31 | ¥4.7bn |
| Enzymatic Medicinereportable segment | capex | 2023-01-01 → 2023-12-31 | ¥341m |
| Enzymatic Medicinereportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥247m |
| Enzymatic Medicinereportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥3.5bn |
| Enzymatic Medicinereportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥3.5bn |
| Enzymatic Medicinereportable segment | segment assets | at 2023-12-31 | ¥3.7bn |
| Enzymatic Medicinereportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥328m |
| Liquorreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥1.2bn |
| Liquorreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥1.2bn |
| Liquorreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥78.8bn |
| Liquorreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥78.8bn |
| Liquorreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥14m |
| Liquorreportable segment | segment assets | at 2023-12-31 | ¥40.7bn |
| Liquorreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥2.6bn |
| Real Estatereportable segment | capex | 2023-01-01 → 2023-12-31 | ¥13m |
| Real Estatereportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥284m |
| Real Estatereportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥1.2bn |
| Real Estatereportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥1.2bn |
| Real Estatereportable segment | segment assets | at 2023-12-31 | ¥6.3bn |
| Real Estatereportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥618m |
| Starch For Processingreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥2m |
| Starch For Processingreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥7m |
| Starch For Processingreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥1.3bn |
| Starch For Processingreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥1.3bn |
| Starch For Processingreportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥6m |
| —segment total | capex | 2023-01-01 → 2023-12-31 | ¥1.5bn |
| —segment total | depreciation | 2023-01-01 → 2023-12-31 | ¥1.8bn |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥84.9bn |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥84.9bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥14m |
| —segment total | segment assets | at 2023-12-31 | ¥50.7bn |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥3.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,684
| Item | Context | Value | Unit |
|---|---|---|---|
| Bonuses sga | CurrentYearDuration | 825000000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration | 38000000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration | 39000000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 172000000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 154000000 | JPY |
| Welfare expenses sga | Prior1YearDuration | 496000000 | JPY |
| Welfare expenses sga | CurrentYearDuration | 526000000 | JPY |
| Taxes and dues sga | Prior1YearDuration | 368000000 | JPY |
| Taxes and dues sga | CurrentYearDuration | 357000000 | JPY |
| Business consignment expenses sga | Prior1YearDuration | 31000000 | JPY |
| Business consignment expenses sga | CurrentYearDuration | 35000000 | JPY |
| Depreciation sga | Prior1YearDuration | 244000000 | JPY |
| Depreciation sga | CurrentYearDuration | 245000000 | JPY |
| Rent expenses sga | Prior1YearDuration | 301000000 | JPY |
| Rent expenses sga | CurrentYearDuration | 299000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 2000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration | 2000000 | JPY |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | Prior1YearDuration | 453000000 | JPY |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | CurrentYearDuration | 523000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00397-000LiquorReportableSegmentsMember | 78799000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00397-000StarchForProcessingReportableSegmentsMember | 1341000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00397-000EnzymaticMedicineReportableSegmentsMember | 3488000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00397-000RealEstateReportableSegmentsMember | 1230000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 84860000000 | JPY |
| Revenues from external customers | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 87000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 84947000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00397-000LiquorReportableSegmentsMember | 14000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00397-000StarchForProcessingReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00397-000EnzymaticMedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00397-000RealEstateReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 14000000 | JPY |
| Transactions with other segments | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -14000000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00397-000LiquorReportableSegmentsMember | 78814000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00397-000StarchForProcessingReportableSegmentsMember | 1341000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00397-000EnzymaticMedicineReportableSegmentsMember | 3488000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00397-000RealEstateReportableSegmentsMember | 1230000000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 84874000000 | JPY |
| Net sales | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 87000000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -14000000 | JPY |
| Net sales | Prior1YearDuration | 84947000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00397-000LiquorReportableSegmentsMember | 2632000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00397-000StarchForProcessingReportableSegmentsMember | -6000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00397-000EnzymaticMedicineReportableSegmentsMember | 328000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00397-000RealEstateReportableSegmentsMember | 618000000 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | 3572000000 | JPY |
| Operating income | Prior1YearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 12000000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |